Background-Racial and ethnic disparities are well documented in many areas of health care, but have not been comprehensively evaluated among recipients of heart transplants.
Racial minority patients with end-stage heart failure who undergo heart transplantation appeared in several studies to have worse long-term survival compared with white recipients, [11] [12] [13] [14] [15] but these studies were relatively small, conducted in selected centers, and examined short time intervals. We therefore sought to examine the association between race and mortality among all adults who underwent primary heart transplantation in the United States since 1987. We also sought to evaluate additional outcomes measures-including recipient cause of death and events during a 2-year followup-in racial and ethnic subgroups to determine their association with disparities in mortality.
Methods

Design Overview, Setting, and Participants
We performed a retrospective cohort study of American adults (age Ն18 years) registered on the United Network of Organ Sharing (UNOS) heart transplantation waiting list (67 588 listed patients) since September 1985. We selected the 39 078 patients who underwent primary heart transplantation (transplanted) between October 1987 and February 2009. Patients were excluded who lacked data on race or ethnicity (3 patients) or did not have any follow-up data (197 patients) . The median follow-up time was 1815 days (interquartile range, 478 to 3304 days). The primary end point of this study was all-cause mortality after transplantation.
Patient data collection and reporting were performed with standard UNOS data worksheets. 16, 17 The data for this study were obtained as a Standard Transplant Analysis and Research file based on Organ Procurement and Transplantation Network data as of May 2009. Each file contains patient-level data on all heart transplantation candidates who have been listed and all transplants performed since October 1, 1987. 18 Clinical staff at each transplantation center determined and coded race/ethnicity using the standard Office of Management and Budget categories as white, black or African American, Hispanic or Latino, Asian, American Indian or Alaskan native, native Hawaiian or Pacific Islander, or multiracial. 19 All patients not coded as white were included in the nonwhite cohort; survival analysis was also performed on nonwhite racial/ethnic subgroups (coded as black, Hispanic or Latino, and other). Nonblack and non-Hispanic minority transplant recipients were categorized as other.
Statistical Analysis
Continuous variables were summarized as meanϮSD and compared by use of Student t tests or ANOVA. Categorical variables were summarized by use of percentages and compared with the use of 2 tests. Time-to-event data were summarized with Kaplan-Meier survival analysis and compared by use of log-rank tests. Dates of transplantation, length of follow-up, and patient outcomes were obtained from the STAR data file. Follow-up on surviving patients was censored on the last date of follow-up reported to UNOS. Patients who underwent a second heart transplantation were censored as alive on the date of retransplantation. In secondary analysis, we evaluated the composite outcome of death or retransplantation.
Multivariable survival analysis was performed with Cox proportional hazards models. Covariates used in the analysis were selected from prior literature on the basis of their known potential to affect mortality 20 ; these included recipient, transplant, and socioeconomic factors. In the final adjusted Cox proportional hazards model, all listed factors were included as covariates. Proportional hazards assumptions were tested by the use of scaled Schoenfeld residuals; variables that failed to meet the proportional hazards assumption were used to stratify the multivariable Cox regressions.
Recipient factors included age, sex, body mass index, history of diabetes mellitus, pulmonary artery diastolic pressure, creatinine, total bilirubin, medical condition (outpatient, inpatient intensive care unit, and inpatient non-intensive care unit), and need for support therapy at transplantation (including dialysis, ventricular assist device, intra-aortic balloon pump, mechanical ventilator, or intravenous antibiotics). Recipient heart disease diagnoses were characterized as ischemic cardiomyopathy, nonischemic cardiomyopathy, valvular heart disease, congenital heart disease, or unknown.
Transplant factors included donor age, graft ischemic time (Ն6 versus Ͻ6 hours), donor-recipient race mismatch, ABO blood group incompatibility (identical versus nonidentical), level of human leukocyte antigen (HLA) antigen mismatches (Յ2, 3 to 4, or Ն5), transplantation era, transplantation center volume, and geographic region using Organ Procurement and Transplantation Network definitions. Transplant centers were categorized into 4 tiers based on their total number of transplantations performed during the study period to account for center volume effects on mortality. 21 Transplant recipients were evenly divided among the following tiers: tier 1, 10 229 patients (26.4%); tier 2, 9525 patients (24.6%); tier 3, 9474 patients (24.4%); and tier 4, 9549 patients (24.6%). Transplantation eras were defined as 1987 to 1995, 1996 to 2000, 2001 to 2004, and 2005 to 2009. 20 Socioeconomic factors included education (college or higher versus high school or lower), US citizenship, insurance type (private versus nonprivate), and median household income. Patient residential ZIP codes were used to evaluate neighborhood-level median household income based on 2000 US Census data. 22 Differences in the frequency of missing data between racial/ ethnic subgroups, when present, were minimal, and appeared to be randomly distributed. An increased frequency of missing data was present for patients receiving transplantations before 1995; thus, multivariable hazard ratios excluding these patients were also estimated.
Unadjusted survival estimates were generated with Kaplan-Meier survival analysis. Adjusted 1-and 5-year survival estimates for white and black transplant recipients, in 3-year increments from 1987 to 2005, were based on the corrected group prognosis method described by Ghali et al. 23 Covariates included recipient age, sex, diagnosis, and medical condition, as well as donor age.
Causes of death were described by racial subgroup and compared by use of a 2 test. Deaths resulting from a cardiovascular cause or graft failure were considered potentially associated with underimmunosuppression; those resulting from infection, posttransplantation lymphoproliferative disorder, or other malignancy were associated with overimmunosuppression according to previous literature. 24 -26 The frequency of hospitalization, hospitalization for a rejection episode, and noncompliance, defined in the UNOS worksheet as "evidence of noncompliance with immunosuppression medication that compromised the patient's recovery" within 2 years of transplantation, were compared. Statistical analyses were performed with Stata/IC 10.1 for Macintosh (Stata Corp, College Station, TX).
Results
During the study period, 14 732 nonwhite (21.9%) and 52 486 white (78.1%) adults were registered on the heart transplantation waiting list. Among the 39 075 patients who underwent heart transplantation, 30 993 were white (79.3%), 4997 black (12.8%), 2118 Latino (5.4%), 649 Asian (1.7%), 140 American Indian or Alaskan native (0.4%), 69 native Hawaiian or Pacific Islander (0.2%), and 109 multiracial (0.3%). Median time on the waiting list was shorter for nonwhite recipients (66 days) than for white recipients (92 days; PϽ0.001).
The total number of heart transplantations performed declined gradually since 1990 ( Figure 1 
Baseline Characteristics
Nonwhite recipients were younger, were more frequently women, and had higher rates of comorbid conditions, including diabetes mellitus and renal failure requiring dialysis (Table 1) . Underlying conditions leading to heart transplantation differed between groups. For example, black patients most frequently underwent transplantation for nonischemic cardiomyopathy (71.0%), whereas white patients most frequently received transplantation for ischemic cardiomyopathy (54.4%; PϽ0.001). Black recipients had the highest rates of HLA antigen mismatches; all nonwhite recipients had high rates of donor-recipient race mismatches compared with white recipients. Black and Hispanic recipients had lower rates of college education and private insurance; they were also from neighborhoods with lower median income.
Mortality
During the study period, 16 880 patients died after transplantation. Black recipients had significantly higher unadjusted mortality than white, Hispanic, or other transplant recipients (log-rank PϽ0.01; Figure 2 ); mortality did not differ significantly between whites and nonblack minority recipients.
One-year mortality among black recipients was 15.8% (95% confidence interval [CI], 14.8 to 16.9), whereas it was 13.2% (95% CI, 12.9 to 13.6) among white, 13 Only black transplant recipients were at an increased risk of death after multivariable adjustment for recipient, transplantation, and socioeconomic variables (hazard ratio, 1.34; 95% CI, 1.21 to 1.47; PϽ0.001; Table 2 ). Hispanic and other recipients were not at an increased risk of death compared with white recipients, although comparisons were limited by fewer numbers of nonblack minority recipients ( Table 2 ). The increased risk of death among black compared with white recipients was of similar magnitude after adjustment for individual transplantation centers (hazard ratio, 1.29; 95% CI, 1.17 to 1.43; PϽ0.001).
Although 1-and 5-year mortality decreased among all recipients during the study period, adjusted mortality estimates among blacks remained consistently higher than among whites ( Figure 3 ). The frequency of retransplantation did not differ between groups; it was performed in 106 black (2.1%), 627 white (2.0%), 45 Hispanic (2.1%), and 24 other (2.5%; Pϭ0.76) recipients. Hazard ratios for the composite outcome of death or retransplantation were similar to the hazard ratios for mortality; compared with white recipients, black recipients had a multivariable hazard ratio for death or retransplantation of 1.35 (95% CI, 1.22 to 1.49; PϽ0.01). Multivariable hazard ratios excluding patients receiving transplantation before 1995 were also similar (1.36; 95% CI, 1.23 to 1.52; PϽ0.01).
Cause of Death
Blacks were more likely to die of graft failure or a cardiovascular cause (57.9%) than were whites (37.8%) or other nonwhites (44.1%; PϽ0.001; Table 3 ) but less likely to die of an infection or malignancy (19.9%) than were whites (33.0%) or other nonwhites (28.2%; PϽ0.001). Similar, but less pronounced, findings were present among recipients surviving Ͼ5 years after transplantation. For example, 48.7% of blacks dying Ն5 years after transplantation died of graft failure or a cardiovascular cause compared with 31.8% of whites (PϽ0.001), whereas 25.8% of blacks died of infection or malignancy compared with 36.3% of whites (PϽ0.001). Noncompliance was the cause of death among 2.2% of black, 0.6% of white, 2.4% of Hispanic, and 0.4% of other recipients (PϽ0.001).
Five-year mortality among blacks was worse than that of whites for all diagnostic groups apart from valvular heart disease. For example, 5-year mortality for blacks with ischemic cardiomyopathy was 35.2% (95% CI, 32.3 to 38.3) compared with 28.0% (95% CI, 27.3 to 28.8) for whites. Among those with nonischemic cardiomyopathy, 5-year mortality in blacks was 37.3% (95% CI, 35.5 to 39.1) compared with 24.1% (95% CI, 23.3 to 25.0) for whites. The adjusted risk of death for blacks compared with whites for nonischemic cardiomyopathy was 1.38 (95% CI, 1.21 to 1.58; PϽ0.001) and for ischemic cardiomyopathy was 1.18 (95% CI, 1.00 to 1.39; Pϭ0.054).
Events During Follow-Up
Within the first 2 years after transplantation, black recipients were hospitalized at a higher rate (40.2%) than other recipients (white, 34.3%; Hispanic, 35.5%; other, 33.2%; PϽ0.001); however, hospitalization data were unavailable for 32% of recipients. Blacks also required hospitalization for rejection (16.1%) more frequently than whites (10.0%), Hispanics (11.1%), and other (9.8%; PϽ0.001) recipients; data on the reason for hospitalization were missing for 67% of recipients. Rates of noncompliance with immunosuppressive medication were also higher among black recipients (15.0%) compared with white (8.9%), Hispanic (10.1%), and other (9.1; PϽ0.001) recipients; data were missing for 30% of recipients.
Discussion
This study found that black adults who received a heart transplant were at an increased risk of death compared with otherwise similar white patients; their long-term mortality was also worse than that of nonblack minority recipients. Although black patients had a higher-risk clinical profile at baseline than white patients, the difference in mortality remained significant after adjustment for recipient, transplant, and socioeconomic factors. After transplantation, black recipients were hospitalized at higher rates, overall as well as specifically for rejection, and more frequently died of causes associated with less effective immunosuppression than other recipients. The increased risk of death 
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among black patients has not changed appreciably over the past 2 decades. Our findings confirm and extend previous smaller studies that suggested an increased mortality among black heart transplant recipients. [11] [12] [13] [14] [15] Park et al 13 Even though other studies have found no increased risk of death among black heart transplant recipients, these studies were single-center studies of between 103 and 525 patients. [27] [28] [29] [30] This present study covers a larger period of time than previous studies and includes substantially more patients.
Although mortality after heart transplantation has decreased progressively over time, the gap in mortality between blacks and whites has persisted. This disparity contrasts with outcomes among recipients of lung transplantation, in whom the increased risk of death before 2001 among nonwhites has been eliminated because mortality among nonwhite lung transplant recipients fell faster than that among white recipients. 31 This improved survival among nonwhite lung transplant recipients may have resulted from changes in immunosuppressive therapy, specifically the decreased use of cyclosporine and the increased use of tacrolimus. Tacrolimus, a calcineurin inhibitor associated with improved outcomes among black organ transplantation patients, 32, 33 has become the predominant therapy for maintenance immunosuppression among lung transplant recipients since 2000. 34, 35 Despite a similar trend of increasing use of tacrolimus among heart transplant recipients-after 1 year, nearly 60% of recipients received tacrolimus in 2007 compared with Ͻ20% in 2000 -the gap in mortality between black and white patients has remained. 20, 35 Blacks were more likely to die of causes potentially associated with underimmunosuppression (graft failure and cardiovascular causes), whereas whites and other nonwhites were more likely to die of causes associated with overimmunosuppression (infection and malignancy). Blacks were also more frequently hospitalized for rejection within 2 years of transplantation. Together, these findings suggest that lower-intensity immunosuppression among blacks recipients may have contributed to the observed disparities in long-term survival. After kidney CI indicates confidence interval. *Adjusted for age, sex, diagnosis group, transplantation era, Organ Procurement and Transplantation Network region, extracorporeal membrane oxygenation use, intra-aortic balloon pump use, mechanical ventilation, medical condition, ABO mismatch, HLA mismatch, body mass index, donor cytomegalovirus status, ischemic time, and list status. †Model 1 plus adjustment for community median income, insurance type, citizenship, education, diabetes mellitus, dialysis, creatinine, intravenous antibiotics at transplantation, pulmonary artery diastolic pressure, graft race mismatch, and center volume.
transplantation, inadequate immunosuppression has been found to contribute to worse allograft survival among blacks. 36 Underimmunosuppression among blacks may result from biological factors, such as higher rates of mismatches between donor and recipient race and HLA antigen status, need for higher levels of immunosuppression, differential drug absorption, and systemic complications of therapy. Underimmunosuppression among blacks may also result from socioeconomic factors, such as inadequate health insurance, poorer access to care, barriers to effective communication between patients and physicians, and lower adherence to treatment. 36 The persistent disparity in mortality might be eliminated if the reason for less adequate immunosuppression among black recipients could be identified. Our study cannot distinguish between biological or socioeconomic factors as the primary reason for lower rates of effective immunosuppression among black recipients. It is notable that previous research suggests that barriers to appropriate cardiovascular care exist for both black and Hispanic patients with heart disease, and that these limitations in access to care may adversely affect mortality. 1, 7, [37] [38] [39] [40] [41] Interestingly, Hispanic transplant recipients in this study had lower rates of college education, US citizenship, and private insurance than black recipients. Nonetheless, Hispanic recipients had a risk of death similar to that of white transplant recipients and lower than that of black recipients.
During the study period, we also found marked changes in the racial composition of heart transplant recipients. Nonwhite patients have increased both in absolute number of heart transplants and as a percentage of all heart transplant recipients; since 2005, nonwhites have accounted for nearly one third of transplantations. Conversely, there has been a steady decline in the number and percentage of white patients placed on the waiting list and ultimately undergoing transplantation. This decline may reflect substantial improvements since 1980 in preventive and acute care for ischemic cardiomyopathy, 42,43 a more common diagnosis among white heart transplant recipients. Notably, however, blacks with either ischemic or nonischemic cardiomyopathy had higher mortality compared with whites. The overall increase in black transplant recipients, however, has not translated into improved outcomes.
Given the persistently worse mortality experienced by black heart transplant recipients over 2 decades, further studies are necessary to investigate the causes, which might focus on 2 areas. First, although nonwhite heart transplant recipients enrolled in recent randomized, controlled trials of immunosuppressive therapy account for up to 14% of the study population, 44 -46 differences in rates of rejection and death by racial subgroups have not been reported. Within the framework of clinical trials, which involve rigorous follow-up and invasive procedures like endomyocardial biopsy or intravascular ultrasound, differences in access to care are likely to be minimized. If present, race-based differences in outcomes may more accurately reflect differences in biological or genetic responses to immunosuppressive therapy. Pooled samples from meta-analyses may offer increased statistical power for evaluating differences in outcomes, but have not been analyzed. 47 Second, given the complex relationship between racial and ethnic factors with disparities in outcomes, 48 additional studies to investigate unmeasured factors contributing to immunosuppression adequacy are necessary. Novel tools, both biological markers of immunosuppression adequacy 49 and survey instruments for noncompliance, 50 for example, are likely to be essential.
This study has a number of important limitations. First, we cannot conclusively identify the reasons for the observed differences in mortality because of the retrospective observational study design. Second, data on patient race and ethnicity from the UNOS data set were determined by staff at transplant centers rather than by patient self-report. Although discrepancies in race/ethnicity coding could result in misclassification, it is unclear whether they would attenuate or magnify the observed effect size. Third, the smaller number of nonblack transplant recipients may have limited the statistical power to determine hazard ratios among minority subgroups. However, we believe that the regression analyses among Hispanic recipients remain robust even after multivariable adjustment, and provide insight about the potential mechanisms that drive mortality differences. Fourth, we were not able to evaluate detailed measures of access to care; instead, we used socioeconomic variables as surrogate measures. It remains possible that unmeasured variables, especially those that favor Hispanic over black recipients, could result in residual confounding. Finally, missing data not only limited our ability to completely assess outcomes but also complicated the ability to identify the causes of observed differences.
Conclusions
Nonwhite and white patients differed significantly in clinical characteristics before transplantation. However, only black adults had higher mortality after heart transplantation compared with whites; this increase was independent of recipient, transplant, and socioeconomic factors. Although long-term survival has improved for all recipients, the racial gap in survival among blacks has persisted over 2 decades, and may be related in inadequate immunosuppression. Additional research aimed at identifying the source of this disparity is necessary.
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